Implementing the generalized pustular psoriasis (GPP) Charter
Read more about the projects are implementing the generalized pustular psoriasis (GPP) Charter
Search
Partnership with IBM to accelerate new antibody therapies
Boehringer Ingelheim collaborates with IBM to advance generative AI and foundation models for therapeutic antibody development
Purpose: Finding the long-missed meaning
Cancer survivor Missy Pappion is happy at Boehringer Ingelheim after climbing the corporate ladder
Keep water clean
Human beings can’t survive without water. Further, the safe production of medicines depends on clean drinking water.
The geography of pet parasites is changing
Climate change facilitates new pet parasites way beyond ticks and flea bites in dogs and cats
ArisGlobal acquires Boehringer Ingelheim technology
Boehringer Ingelheim’s signal analytics technology is acquired by ArisGlobal
Digital innovation: Our digital pipeline is only growing
BRASS, a software advancing patient safety and developed fully in-house, has been sold. This is proof: our digital innovations are in demand.
Brigitte Fuhr
Brigitte Fuhr, our Head of Central Data Science, joined our team to make millions of lives better. Now she’s working on a global program that will transform our ability to develop ground-breaking treatments.
Advancing green chemistry for more sustainable medicines
By applying the principles of eco-design and green chemistry, we developed an innovative manufacturing process with reduced environmental footprint.
10 tips cat friendly veterinary clinics
Here are 10 simple steps you can take to make feline patients feel at ease at your practice.
New cancer therapeutics collaboration with 3T Bio
Boehringer Ingelheim and 3T Biosciences collaborate to discover and develop next-generation cancer therapies to address high unmet patient needs
Global mobility
We are a global company with a global outlook. We welcome the breadth of perspective that international experience brings to our teams.
CAROLINA-CARMELINA-Asia-analysis
CAROLINA® and CARMELINA® outcome trial subgroup analyses demonstrate cardiovascular and renal safety data in Asian adults with type 2 diabetes
Facts about the INPULSIS™ trials
New Therapeutic Antibody Discovery Collaboration
Proprietary antibody libraries to help discover therapeutic antibodies against multiple targets
clinical-collaboration-with-Amgen
Collaboration to study Boehringer Ingelheim’s SOS1::pan-KRAS Inhibitor in combination with Amgen’s KRASG12C Inhibitor
Social Media Data Privacy and Cookies Statement
The Boehringer Ingelheim Veterinary Scholars Program
The aim of the Boehringer Ingelheim Veterinary Scholars Program is to expose students to biomedical research
Boehringer Ingelheim collaborates with Circle Pharma
Boehringer Ingelheim collaborates with Circle Pharma to develop a first-in-class cyclin RxL inhibitor that can halt the growth of cancer cells
Clinical-phase2-trials-NASH-and-obesity
Boehringer Ingelheim and Zealand Pharma announced Phase 2 trials of the GLP-1/glucagon dual agonist BI 456906 for adults living with obesity or NASH.
Phase 1 start for novel triple agonist obesity treatment
Boehringer and Gubra announce Phase 1 study of BI 3034701, a long-acting, next generation, first-in-class triple agonist peptide for obesity treatment
1885-1948: Innovative beginnings
The Boehringer Ingelheim history from its start in 1885 to 1948, with milestones and important products
U.S. FDA approves first treatment for generalized pustular psoriasis flares in adults
Boehringer Ingelheim announces the U.S. FDA has approved the first treatment for generalized pustular psoriasis (GPP) flares in adults
New spesolimab data show significant improvement in GPP flares
New spesolimab data show significant improvement in GPP flares
Our goal of transforming the treatment of neuroendocrine carcinomas
Our progress in developing a potential DLL3 targeted immunotherapy for neuroendocrine carcinomas (NECs), including small cell lung cancer (SCLC), large cell NEC of the lung (LCNEC-L) and extrapulmonary NEC (epNEC).